Luděk Pour

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 949 citations · Full text

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 430 citations · Full text

Hematological Malignancy, Overall Survival, Medicine +7

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau et al. · Blood · 2019 · 125 citations · Full text

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma

Aneta Mikulášová, Christopher P. Wardell, Alexander Murison et al. · Haematologica · 2017 · 97 citations · Full text